EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.

Launched by IRCCS SAN RAFFAELE ROMA · Oct 4, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a medication called eptinezumab, which is being tested to see how effective and safe it is for people who suffer from migraine disorders in everyday life. The researchers want to find out if eptinezumab can help reduce the frequency and severity of migraines in patients who experience these debilitating headaches often.

To be eligible for this study, participants need to be between 18 and 75 years old, and they should have experienced at least 8 days of disabling migraines each month over the past three months, or have chronic migraines as defined by specific criteria. Both men and women can participate, as long as they agree to sign consent forms. Participants can expect to be monitored closely throughout the trial to ensure their safety and to track how well the treatment is working. It’s important to note that individuals with other types of headaches, certain medical conditions, or who are currently taking other specific treatments may not be able to join the study.

Gender

ALL

Eligibility criteria

• • KEY INCLUSION CRITERIA
• • 1. Age between 18 and 75 years;
• • 2. Males and females;
• • 3. Willingness to sign the informed consent;
• • 4. High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months;
• • 5. Chronic migraine, according to the ICHD-III criteria;
• • KEY EXCLUSION CRITERIA
• • 1. Other headaches different than migraine;
• • 2. Known intolerance to eptinezumab or eccipients;
• • 3. Current treatment with other mAbs;
• • 4. Vascular disease or Raynaud.